ImmunoPrecise Antibodies Past Earnings Performance
Past criteria checks 0/6
ImmunoPrecise Antibodies's earnings have been declining at an average annual rate of -31%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 13.5% per year.
Key information
-31.0%
Earnings growth rate
-17.9%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 13.5% |
| Return on equity | -84.5% |
| Net Margin | -115.2% |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ImmunoPrecise Antibodies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 24 | -28 | 19 | 5 |
| 30 Apr 24 | 25 | -27 | 19 | 4 |
| 31 Jan 24 | 24 | -14 | 21 | 2 |
| 31 Oct 23 | 23 | -16 | 21 | 3 |
| 31 Jul 23 | 22 | -21 | 21 | 7 |
| 30 Apr 23 | 21 | -27 | 18 | 14 |
| 31 Jan 23 | 20 | -26 | 19 | 15 |
| 31 Oct 22 | 20 | -25 | 19 | 15 |
| 31 Jul 22 | 19 | -23 | 18 | 13 |
| 30 Apr 22 | 19 | -17 | 18 | 8 |
| 31 Jan 22 | 19 | -17 | 17 | 7 |
| 31 Oct 21 | 19 | -15 | 16 | 5 |
| 31 Jul 21 | 19 | -10 | 15 | 3 |
| 30 Apr 21 | 18 | -7 | 13 | 2 |
| 31 Jan 21 | 17 | -3 | 12 | 1 |
| 31 Oct 20 | 17 | -3 | 10 | 1 |
| 31 Jul 20 | 15 | -3 | 9 | 1 |
| 30 Apr 20 | 14 | -5 | 9 | 0 |
| 31 Jan 20 | 13 | -8 | 9 | 1 |
| 31 Oct 19 | 11 | -8 | 9 | 1 |
| 31 Jul 19 | 11 | -9 | 9 | 1 |
| 30 Apr 19 | 11 | -8 | 9 | 0 |
| 31 Jan 19 | 10 | -6 | 9 | 1 |
| 31 Oct 18 | 9 | -6 | 9 | 0 |
| 31 Jul 18 | 8 | -5 | 8 | 0 |
| 30 Apr 18 | 5 | -5 | 6 | 1 |
| 31 Jan 18 | 4 | -4 | 5 | 1 |
| 31 Oct 17 | 3 | -7 | 4 | 1 |
| 31 Jul 17 | 2 | -6 | 2 | 1 |
| 30 Apr 17 | 3 | -5 | 2 | 1 |
| 31 Jan 17 | 3 | -4 | 1 | 0 |
| 31 Oct 16 | 3 | 1 | 1 | 0 |
| 31 Jul 16 | 2 | 0 | 1 | 0 |
| 30 Apr 16 | 2 | 0 | 1 | 0 |
| 30 Apr 15 | 2 | 0 | 1 | 0 |
Quality Earnings: TQB is currently unprofitable.
Growing Profit Margin: TQB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TQB is unprofitable, and losses have increased over the past 5 years at a rate of 31% per year.
Accelerating Growth: Unable to compare TQB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TQB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.9%).
Return on Equity
High ROE: TQB has a negative Return on Equity (-84.5%), as it is currently unprofitable.